Exclusive Summary

• - US-registered Lacosamide Injection 200mg/20ml (10 mg/ml) is post-LOE in major markets, offering mature timing and strong compliance credentials.
• - Recognized as a second-line IV option for status epilepticus and for short-term substitution when oral dosing is not feasible, meeting hospital ED/ICU needs.
• - Among ~50 million people with epilepsy (≈60% focal in adults), the injectable serves acute care and perioperative settings globally.
• - While multiple generics exist, IV suppliers are fewer than orals; “US registration” plus reliable sterile capacity creates a tender/distribution edge.
• - Typical 60–90% price erosion versus originator enables cost-effective hospital procurement and competitive positioning in emerging markets.